Business Wire

SFL

Share
SFL – First-Half 2020 Results

Regulatory News:

The interim consolidated financial statements for the six months ended 30 June 2020 were approved by the Board of Directors of Société Foncière Lyonnaise (Paris:FLY) on 28 July 2020, at its meeting chaired by Juan José Brugera.
In a market thrown into turmoil by the Covid-19 crisis, rental income and EPRA earnings declined but the portfolio’s appraisal value continued to rise and the Group’s NAV remained stable, attesting to SFL’s strategic resilience.
The auditors have completed their review of the financial statements and issued their report on the interim financial information, which does not contain any qualifications or emphasis of matter.

Consolidated data (€ millions)

 

 

H1 2020

H1 2019

Change

Rental income

91.2

97.9

-6.9%

Adjusted operating profit*

74.8

83.3

-10.1%

EPRA earnings

50.1

57.2

-12.5%

Attributable net profit

113.7

253.5

-

* Operating profit before disposal gains and losses and fair value adjustments

 

 

 

30/06/2020

31/12/2019

Change

Attributable equity

4,473

4,485

-0.3%

Consolidated portfolio value excluding transfer costs

7,239

7,158

+1.1%

Consolidated portfolio value including transfer costs

7,715

7,632

+1.1%

EPRA NNNAV

4,452

4,461

-0.2%

EPRA NNNAV per share

€95.7

€95.9

Results:

Rental income:

First-half 2020 consolidated rental income amounted to €91.2 million, down €6.7 million (6.9%) from the €97.9 million reported for the same period of 2019.

- On a like-for-like basis (excluding changes in consolidation scope affecting period-on-period comparisons), rental income contracted by €2.6 million (2.9%). The decline was due to the effects of the Covid-19 crisis, which led to rent holidays being granted to tenants of small retail units (with a marginal overall impact) and the closure of the Edouard VII and #cloud.paris conference centres as well as the Indigo hotel. Adjusted for the impacts of the conference centres, Indigo hotel and Edouard VII car park closures, like-for-like rental income increased by €0.3 million.

- Rental income from units being redeveloped or renovated in the periods concerned was down by €3.5 million, due to the renovation of several floors that were vacated in late 2019 and early 2020, mainly in the 103 Grenelle building.

- Lastly, income from various penalties was down by a slight €0.6 million in first-half 2020.

Operating profit before disposal gains and losses and fair value adjustments to investment property came to €74.8 million in first‑half 2020 versus €83.3 million in the year‑earlier period.

Portfolio appraisal value:

The portfolio’s appraisal value at 30 June 2020 was 1.1% higher on a like-for-like basis than at 31 December 2019. Positive fair value adjustments to investment property amounted to €42.8 million at 30 June 2020 versus positive adjustments of €234.5 million at 30 June 2019.

Net profit:

Net finance costs amounted to €13.7 million in first-half 2020 compared with €15.2 million in the year‑earlier period, a decrease of €1.5 million. The €0.4 million increase in recurring finance costs, mainly reflecting the Group’s higher level of debt, was partly offset by the lower average cost of debt.

After taking into account these core items, the Group reported EPRA earnings of €50.1 million in first‑half 2020, down 12.5% from €57.2 million in the year-earlier period. Attributable net profit for the period came in at €113.7 million compared with €253.5 million in first‑half 2019.

Business review:

Rental operations:

Despite the Covid-19 crisis which severely disrupted the Paris region rental market, SFL signed leases on around 16,000 sq.m. in first‑half 2020 on very good terms. The 10,000 sq.m. of offices let during the period included over 80% (6,500 sq.m.) of the office space in the 83 Marceau building currently in the process of being redeveloped, which has been let to Goldman Sachs under a turnkey lease.

The new office leases were signed at an average nominal rent of €867 per sq.m, corresponding to an effective rent of €754 per sq.m. These prices attest to the Paris rental market’s resilience and the very high quality of the Group’s properties.

The physical occupancy rate for revenue-generating properties stood at 95.0% at 30 June 2020 compared with 97.4% at 31 December 2019. The remaining vacant units are located mainly in the Le Vaisseau building in Issy-les-Moulineaux and the 103 Grenelle building where around 6,000 sq.m. of newly renovated offices have just been delivered. The EPRA vacancy rate was 4.5% at June 30, 2020 versus 1.6% at 31 December 2019.

Development operations:

Properties undergoing development at 30 June 2020 represented roughly 17% of the total portfolio. They consist mainly of the Group’s current three flagship projects concerning:

- The retail space in the Louvre Saint-Honoré building, which is scheduled for delivery at the end of 2023 under a turnkey lease on over 20,000 sq.m. Work has just begun on clearing the space to be redeveloped and removing asbestos.
- The Biome office complex on avenue Emile Zola (approximately 24,000 sq.m.), which is being completely redeveloped. The partial demolition phase has already been completed and the building is due to be delivered in 2022.
- The office building at 83 avenue Marceau (approximately 9,000 sq.m.), which is in the process of being redeveloped, with delivery scheduled for 2021. Most of the units have been pre-let, including almost 6,500 sq.m. (81% of the building's total surface area) let under a turnkey lease signed in first-half 2020.

Development costs capitalised in first-half 2020 amounted to €32.5 million, including the above projects for a total of €18.4 million and large-scale renovations of complete floors in the Washington Plaza, 103 Grenelle and 106 Haussmann buildings.

Work on these projects was halted for approximately two months during the Covid-19 lockdown. Once the lockdown was lifted, the various teams gradually returned to work as conditions allowed and site activity was almost back to normal levels in June. The resulting delivery delays were kept to a reasonable three-to-six months depending on the project.

Portfolio operations:

No properties were purchased or sold in first-half 2020.

Financing:

During the period, SFL issued €500 million worth of 1.50% seven-year bonds due on 5 June 2027.

In addition, a new five-year €150 million revolving line of credit was obtained from BNP Paribas. This new facility cancels and replaces a previous €150 million revolving line of credit that was reduced to €100 million in 2019 and was due to expire in May 2021.

The bond issue and revolving line of credit will be used for general corporate purposes. They have extended the average maturity of the Group's debt as part of its proactive balance sheet management strategy.

Net debt at 30 June 2020 amounted to €1,877 million (compared with €1,732 million at 31 December 2019), representing a loan-to-value ratio of 24.3%. At June 30, 2020, the average cost of debt after hedging was 1.5% and the average maturity was 4.7 years. At the same date, the interest coverage ratio stood at 5.6x.

At 30 June 2020, SFL had €1,040 million in undrawn lines of credit.

EPRA NNNAV:

The consolidated market value of the portfolio at 30 June 2020 was €7,239 million excluding transfer costs, an increase of 1.1% from €7,158 million at 31 December 2019 that was primarily due to the value created by work on the Group’s flagship projects. The market value of its revenue-generating office properties was stable compared with end-2019.

The average EPRA topped-up net initial yield (NIY) was 3.0% at 30 June 2020, unchanged from 31 December 2019.

EPRA NNNAV stood at €4,452 million or €95.7 per share at 30 June 2020 versus €95.9 per share at 31 December 2019, reflecting a very small 0.2% decrease over the past six months after payment of a dividend of €2.65 per share in April 2020. After adding back the dividend payout, EPRA NNNAV was up 2.6% over the period.

Management of the Covid-19 health crisis:

As soon as the crisis emerged, SFL took all necessary measures to limit the pandemic’s effects on its business and results:

- All the office buildings remained open and available for use by tenants, and the necessary health protection measures were deployed in the buildings’ common areas.
- The conference centres (Edouard VII and #cloud.paris) and the Indigo hotel (Edouard VII) were closed.
- Government measures concerning very small businesses and small retail outlets were applied and tenant requests for help were managed on a case-by-case basis in order to provide them with the necessary support as far as possible, for example by allowing them to defer payment of their second quarter rent.
- Property leasing activities continued in a very slow rental market.
- Agreements were signed with the general contractors working on the main redevelopment projects currently in progress.
- The Group’s financial liquidity was strengthened.

As a result of these measures, the top-line impact of the crisis was limited to €3.7 million in “lost” rental income, leading to a €2.5 million reduction in net property rentals.

A citizen-based approach:

To ensure business continuity while also protecting employees, all of SFL’s teams worked from home during the lockdown, with no temporary lay-offs, since the lockdown was lifted, they have been gradually returning to the office.

Lastly, SFL contributed to the collective effort to fight the pandemic, by donating €550,000 to the Fondation de France’s programmes in support of hospitals and health workers, medical research and assistance for vulnerable people. The Group also offered to make one of its vacant properties available to the Paris urban affairs ministry to provide emergency housing.

EPRA indicators

H1 2020

H1 2019

EPRA Earnings (€m)

50.1

57.2

/share

€1.08

€1.23

EPRA Cost Ratio (including vacancy costs)

16.1%

13.2%

EPRA Cost Ratio (excluding vacancy costs)

14.3%

12.5%

30/06/2020

31/12/2019

EPRA NAV (€ millions)

4,606

4,623

/share

€99.0

€99.4

EPRA NNNAV (€ millions)

4,452

4,461

/share

€95.7

€95.9

EPRA Net Initial Yield (NIY)

2.6%

2.7%

EPRA topped-up NIY

3.0%

3.0%

EPRA Vacancy Rate

4.5%

1.6%

Alternative Performance Indicators (APIs)

API EPRA earnings

€ millions

H1 2020

H1 2019

Attributable net profit

113.7

253.5

Less:

 

 

Profit (loss) on asset disposals

-

-

Fair value adjustments to investment property

(42.8)

(234.5)

Fair value adjustments to financial instruments, discounting adjustments to debt and related costs

0.2

2.1

Tax on the above items

(9.0)

12.5

Non-controlling interests in the above items

(12.0)

23.6

EPRA earnings

50.1

57.2

API EPRA NNNAV

€ millions

30/06/2020

31/12/2019

Attributable equity

4,473

4,485

Treasury shares

4

8

Unrealised capital gains

23

23

Fair value adjustments to fixed rate debt

(48)

(55)

EPRA NNNAV

4,452

4,461

API net debt

€ millions

30/06/2020

31/12/2019

Long-term borrowings and derivative instruments

1,936

1,441

Short-term borrowings and other interest-bearing debt

258

393

Debt in the consolidated statement of financial position

2,194

1,834

Less:

 

 

Current account advances (liabilities)

(50)

(50)

Accrued interest, deferred recognition of debt arranging fees, negative fair value adjustments to financial instruments

2

1

Cash and cash equivalents

(270)

(54)

Net debt

1,877

1,732

More information is available at www.fonciere-lyonnaise.com

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 13:00:00 CET | Press release

Expanded collaboration builds on Acepodia and Biocytogen’s recent co-development efforts to evaluate selected bispecific antibody and dual-payload ADC programs Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreem

Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 11:08:00 CET | Press release

Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played

Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 10:44:00 CET | Press release

At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will

Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 10:00:00 CET | Press release

Anthropic’s safety-first AI meets Allianz's dedication to customer centricity, stakeholder trust, and regulatory excellenceThree focus areas of the partnership: workforce empowerment, operations automation through agentic AI, and regulatory compliance Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE.

MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 07:00:00 CET | Press release

MH002 is currently the most advanced Live Biotherapeutic Product (LBP) based on a rationally-designed combination of disease specific bacteria (microbial consortia), for the treatment of inflammatory bowel diseases (IBD) STARFISH-UC Phase 2b trial is designed to confirm MH002’s early efficacy signals and favorable safety observed in Phase 2a studies MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind,

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye